Propranolol and performance anxiety: the history of off-label beta-blocker use

A drug designed for the heart

Propranolol did not begin as a treatment for anxiety of any kind. It was designed as a cardiovascular medication. The work is generally credited to the British pharmacologist Sir James Black, whose research in the late 1950s and 1960s was aimed at reducing the heart's demand for oxygen in people with angina, the chest pain associated with reduced blood supply to heart muscle. Before this class existed, the options for angina were limited, and Black's approach represented a different way of thinking about the problem.

That approach drew on an earlier idea. In 1948 the American scientist Raymond Ahlquist had proposed that the body's response to adrenaline and noradrenaline was mediated by two distinct kinds of receptors, which he called alpha and beta. Black is generally described as having taken this theory and asked whether a molecule could be built to occupy the beta receptors and blunt the heart's response to catecholamines. Propranolol, which reached the market in the mid-1960s, became the widely used embodiment of that idea, and Black was awarded the Nobel Prize in Physiology or Medicine in 1988 for the body of work it represented.

This guide is educational and traces a piece of pharmacological history. It is not medical advice, and it does not recommend propranolol, or any beta blocker, for any particular person or purpose. The point of the origin story is simply that a medication now discussed in many contexts was, by design, a heart drug first.

How new uses emerged over time

Once propranolol was in wide clinical use, physicians began to observe effects that reached beyond its original cardiovascular purpose. Over the following years the same molecule came to be discussed in connection with a long list of conditions, including:

• High blood pressure
• Certain irregular heart rhythms
• Migraine prevention
• Essential tremor
• The physical symptoms of an overactive thyroid

Several of these connections are generally described in historical accounts as having been noticed serendipitously rather than sought out in advance.

The thread relevant to performance anxiety is usually traced to observations made while the drug was being used for other reasons. Early reports in the 1960s, associated with investigators such as Turner and Granville-Grossman, noted that beta-adrenergic blockade appeared to dampen some of the bodily sensations people describe during anxiety, at a time when the drug was being studied in settings such as rapid heartbeat linked to thyroid overactivity. These were observations about the peripheral, physical layer of the stress response, and they set the stage for a distinct line of inquiry.

It is worth being precise about what that means. An observation that a medication affects a particular physical signal is not the same as an approved use, and it is not a claim that the medication is appropriate for anyone. It is the beginning of a research question. The history that follows is the story of that question being examined, not of a settled conclusion.

The peripheral adrenergic-response angle

The reason propranolol entered the performance-anxiety conversation at all is mechanistic, and it connects directly to what the drug was built to do. Many of the sensations people associate with acute situational anxiety — a pounding or racing heartbeat, trembling hands, a shaky voice, sweating — are understood to be peripheral expressions of sympathetic, catecholamine-driven signaling. These are bodily responses mediated in part through beta-adrenergic receptors in the heart and other tissues, the very receptors a beta blocker is understood to occupy.

This is why the historical discussion is described as centering on the periphery rather than the brain. Beta blockers are generally characterized as acting on the body's adrenergic signaling at the level of receptors on organs and tissues, not on the central brain chemistry usually associated with anxiety disorders. In the literature this distinction is often framed as a peripheral rather than a central mechanism: the class is discussed in relation to the physical symptoms of a stress response, and separately from the thoughts, mood, or worry that may accompany them.

Framing the story this way keeps it honest. Describing a mechanism explains why researchers and clinicians found the question worth asking; it does not establish that any individual will notice any particular effect, which is not something a mechanism description can do. Our separate guide on how beta blockers are understood to act on beta-adrenergic receptors covers the underlying receptor biology in more detail; this article stays with the historical and situational context.

Performers, students, and the situational-anxiety literature

By the 1970s, the idea had reached the performing arts, and much of the folklore around beta blockers and stage fright dates to this period. Accounts from the era describe classical musicians experimenting with propranolol before performances, and by the end of the decade the topic had surfaced in mainstream and music-community writing, including pieces framed around the question of whether the drug had a place in managing stage fright. These accounts are historical and often anecdotal, and they are reported here as part of the record rather than as evidence of anything.

A small body of formal research followed. A frequently cited example is a 1982 double-blind crossover study by Brantigan and colleagues, which examined propranolol alongside terbutaline, a beta-2 agonist, among musicians before recitals and looked at self-reported measures of nervousness and physical steadiness. Other small studies from the 1970s and 1980s examined related questions, including situational anxiety in students facing examinations. Reviews generally describe this literature as limited in size and dated, and they note that it has not resolved the question for clinical practice.

For that reason, none of this history should be read as a promise. The studies were small, the settings specific, and the outcomes measured were narrow; describing that a question was investigated is not the same as claiming a result for any person today. What the record does show is a clear mechanistic rationale for why the peripheral, physical symptoms of situational anxiety became a subject of study for a drug originally built for the heart.

What 'off-label' means in this story

Throughout this history, propranolol's use in the context of anxiety has been what clinicians call off-label. A medication receives regulatory approval for specific uses supported by the data submitted for it; propranolol's approvals in the United States sit on the cardiovascular and related side of its history. Prescribing an approved medication for a purpose outside those specific approvals, based on a licensed clinician's judgment, is described as off-label use. It is a normal and legal part of medical practice, but it is not the same as an approved indication.

The practical meaning is straightforward: in most countries, and in the United States, propranolol is not approved specifically for the treatment of anxiety or performance anxiety, and describing its history in this context does not change that. Off-label status also underscores where the decision sits. Whether a beta blocker has any role for a particular person, and if so which agent and what strength, is a clinical determination that depends on that person's full medical history, current medications, and other factors — the kind of assessment only a licensed provider who has reviewed the individual can make.

None of this is a directive. This guide does not tell anyone to seek, take, or avoid propranolol, and it does not describe amounts, timing, or frequency of use. It describes how a class of medication came to be discussed in a context outside its original design, and it leaves every clinical decision where it belongs — with an independent licensed provider.

How prescription review works on OpenDoseRx

OpenDoseRx is a platform for requesting prescription products through a structured review process; it does not itself practice medicine. The steps are the same across the catalog. First, you choose a product and strength and complete a medical intake, a set of questions about your health history and current situation. That intake is then reviewed by an independent licensed U.S. provider.

The provider makes the clinical decision. If the provider determines a request is appropriate, the approved order is filled by a licensed U.S. pharmacy. If the provider declines the request, the order is refunded in full. Any decision about whether a medication fits your situation, and any decision about dosing, is made by that provider — not selected by you and not determined by this guide.

This process is educational and is not a substitute for your own healthcare provider or for an in-person evaluation. Where a product is a compounded preparation, it is not an FDA-approved drug, and statements about it have not been evaluated by the FDA. Nothing here should be read as a promise of any particular outcome; it is a description of how a medication class came to be studied and how a request is reviewed.